Salicylic Acid Acne Products From Korea: FDA OTC Rules, Step by Step

A salicylic acid cleanser can be a cosmetic in Seoul and a drug in New Jersey. Same formula. Same factory. Same tube. The only thing that changes is the claim on the box.

Korea gives acne-relief products a middle lane: they are functional cosmetics, limited to cleansing products. The US has no middle lane. If the label promises to clear pimples, the product is a drug, and a different rulebook applies from the factory floor to the back panel.

My advice to founders planning an acne line is to decide the claim before you brief the formula.

Why Does a Korean Acne Product Become a Drug in the US?

Intended use decides it. US law defines a drug as a product intended to treat or prevent disease. The federal acne rules define acne as a disease of the oil glands and hair follicles (21 CFR 333.303). So a US label that says "clears breakouts" turns a cosmetic into an OTC drug.

FDA reads intended use from more than the label. Claims in advertising, on the internet, and in other promotional materials count, and so does consumer perception (FDA). Your product page counts. So does the script you send a creator.

Korea draws the line elsewhere. Acne-relief products moved from quasi-drugs into Korea's functional cosmetic category in 2017 (ChemLinked). That category covers body cleansing products only, and the label must say the product is not a drug for preventing or curing disease (ChemLinked). Ship the same box to the US and the acne wording makes it an unapproved drug unless it meets US drug rules.

Two Paths: Cosmetic Claims or the OTC Acne Monograph

Every BHA product headed to the US takes one of two paths. The cosmetic path keeps claims about look and feel and follows MoCRA. The OTC path allows acne claims but adds drug registration, drug listing, Drug Facts labeling, drug manufacturing rules, and a facility fee.

The cosmetic path uses the same import steps as any K-beauty launch, covered in our FDA guide to importing Korean skincare. Sunscreens are OTC drugs too, so if you have launched a Korean SPF, the sunscreen OTC monograph path will feel familiar.

What Does the US Acne Monograph Actually Allow?

The acne monograph is a closed list. It allows benzoyl peroxide at 2.5 to 10 percent, salicylic acid at 0.5 to 2 percent, sulfur at 3 to 10 percent, and two resorcinol and sulfur combinations (21 CFR 333.310). An acne claim built on any other active needs an approved new drug application.

An OTC monograph is a rule that sets the active ingredients, strengths, and label wording a nonprescription drug may use without FDA premarket approval (FDA). Stay inside it and you skip the approval process. Step outside it and you are selling an unapproved drug.

Betaine salicylate is a compound of betaine and salicylic acid that appears in some Korean BHA formulas. It is not on the monograph list. If your Korean lab proposes it, the product stays a cosmetic in the US, and its copy has to stay cosmetic too. The same logic applies to azelaic acid, which is also off the acne monograph.

The monograph fixes the words too. The label calls the product an "acne medication" or "acne treatment," states "For the treatment of acne," and carries "For external use only" (21 CFR 333.350).

The Seven-Step OTC Protocol, From Seoul Factory to US Shelf

The OTC route runs in seven steps, and the order matters. Claim first, factory second, formula third, paperwork last.

1. Lock the US claim set. Pick your indication and optional statements from the monograph menu, such as "helps prevent new acne blemishes," before anyone adjusts the formula (21 CFR 333.350).
2. Confirm the factory is an FDA drug establishment. Ask for its registration and check it on FDA's Drug Establishments Current Registration Site, updated each business day (FDA DECRS). A foreign establishment must register before its drug is offered for import, naming a US agent and its importers (FDA).
3. Fit the formula to the monograph. Set salicylic acid inside 0.5 to 2 percent. Then ask how the lab will test it. Drug cGMP requires each batch to be tested for the identity and strength of the active before release (21 CFR 211.165).
4. Get a labeler code and NDC. A labeler code identifies the company marketing the drug, and FDA requires one before a drug is listed for the first time (FDA). Decide now whether the code sits with your brand or with the factory.
5. Build the Drug Facts panel. OTC labels follow the Drug Facts format in 21 CFR 201.66 (eCFR). If the product also makes cosmetic claims, list the active under "Active Ingredients" and the rest as "Inactive Ingredients."
6. List the drug and run cGMP batches. The drug listing is an electronic submission tied to your NDC. Production follows drug cGMP in 21 CFR parts 210 and 211: batch records, release testing, and a written stability program (eCFR).
7. Plan for the OMUFA facility fee. FDA charges an annual fee to owners of facilities that make finished OTC monograph drugs, contract manufacturers included, regardless of company size (FDA OMUFA). The first FY 2027 installment fell due on October 1, 2026. Ask how the fee shows up in your quote.

Which Mistakes Stop a K-Beauty Acne Launch?

The expensive mistakes here are about wording and paperwork, not chemistry. A compliant formula with drug wording on a cosmetic label is still a misbranded product.

• Translating Korean acne copy word for word. "Helps relieve acne" is legal functional cosmetic wording in Korea. On a US cosmetic label it is a drug claim. Rewrite it into appearance language and check it against the US cosmetic labeling rules.
• Pairing betaine salicylate with acne claims. It is not a monograph active, so no acne claim can ride on it.
• Letting marketing make the claim. Product page FAQs, ads, and creator scripts all establish intended use. FDA posts warning letters about drug claims made for products marketed as cosmetics (FDA).
• Filing the OTC SKU as a cosmetic. FDA notes that MoCRA's exemptions extend to certain products and facilities subject to drug requirements (FDA). Your acne SKU belongs in drug registration and listing, while your regular cosmetics stay in MoCRA registration and listing.
• Shipping before the paperwork is live. FDA keeps Import Alert 66-41 for detaining unapproved new drugs promoted in the US (FDA). Acne claims on a product that misses the monograph land it in that category.

Before the PO, During Production, After Launch: The Compliance Calendar

OTC work falls into three phases, and the heaviest one comes before the purchase order.

Before the PO. Claim set, a DECRS check on the factory, a monograph-fit formula, the labeler code, a draft Drug Facts panel, and a quote that shows the facility fee.

During production. Batch records, release testing of the active, the stability program, and a drug listing that matches the final label.

After launch. Establishment registration renews between October 1 and December 31 each year (FDA). Update the listing when the label or formula changes. Budget the fee each fiscal year, and audit ads for claims your label does not make.

Should Your First Acne SKU Be a Cosmetic or an OTC Drug?

Pick the cosmetic path when the product's job is daily exfoliation and texture. Pick the OTC path when the whole promise is clearing breakouts, because a cosmetic cannot make that promise in the US.

• Your hero claim. If the product cannot sell without the word "acne," go OTC.
• Your factory shortlist. The OTC path limits you to FDA-registered drug establishments.
• Your active. Betaine salicylate, or salicylic acid outside 0.5 to 2 percent, keeps you on the cosmetic path.
• Your timeline. The OTC path adds a labeler code, a drug listing, and Drug Facts work before the first shipment.

Format matters too. Cleansers convert most easily, since Korea's acne category already covers cleansing products and the US monograph includes products applied and removed from the skin. Leave-on BHA toner pads can go OTC if the formula fits, or stay cosmetic with exfoliation claims. Soothing products built on heartleaf (houttuynia cordata) stay cosmetic when the copy is about calming the look of redness.

Frequently Asked Questions

Does a salicylic acid acne cleanser need FDA approval before launch?
No premarket approval is needed if the product conforms to the acne monograph. It still needs a registered drug establishment, a labeler code and NDC, a drug listing, Drug Facts, and drug cGMP manufacturing (FDA).

Can a K-beauty product be a cosmetic and an OTC drug at the same time?
Yes. FDA treats a product with both cosmetic and drug intended uses as both, like a moisturizer with sun-protection claims, and it must meet both sets of rules. The active is listed under "Active Ingredients" and the rest under "Inactive Ingredients."

Who pays the OMUFA facility fee, the brand or the Korean factory?
FDA assesses it on the owner of the facility that makes the finished OTC monograph drug, including contract manufacturers (FDA). A brand that owns no facility pays only through pricing, so ask before you sign.

How fast does a Korean factory's drug registration show up?
FDA says a successful registration appears on DECRS by the end of the next business day. The entry shows an expiration date of December 31 of the following year (FDA).

By Liz Song, K-beauty sourcing consultant.